UBS AM
RGLS

UBS AM’s Regulus Therapeutics RGLS Stock Holding History

UBS AM’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,209
Closed -$479K – 2627
2016
Q3 		$479K Sell
1,209
-378
-24% -$155K ﹤0.01% 2004
2016
Q2 		$550K Sell
1,587
-20,797
-93% -$14.9M ﹤0.01% 1915
2016
Q1 		$18.6M Buy
22,384
+209
+0.9% +$166K 0.02% 688
2015
Q4 		$23.2M Buy
22,175
+3,733
+20% +$3.74M 0.03% 616
2015
Q3 		$14.5M Buy
18,442
+6,261
+51% +$6.43M 0.02% 771
2015
Q2 		$16M Buy
12,181
+3,036
+33% +$4.9M 0.02% 781
2015
Q1 		$18.6M Buy
9,145
+1,072
+13% +$2.33M 0.02% 732
2014
Q4 		$15.5M Buy
+8,073
New +$14.4M 0.01% 760

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

UBS AM's RGLS Position: Q4 2016 in Review

UBS AM sold out of Regulus Therapeutics (RGLS) in Q4 2016, closing a stake of 1,209 shares — an estimated $479K sold.

UBS AM first reported a position in RGLS in Q4 2014 and held it in 8 quarters. The position peaked at $23.2M in Q4 2015. 68 funds tracked by Wall St. Rank hold RGLS as of Q4 2016.

  • UBS AM reported no remaining Regulus Therapeutics position as of Q4 2016 after selling out during the quarter.
  • UBS AM sold 1,209 Regulus Therapeutics shares in Q4 2016, an estimated $479K.
  • UBS AM first reported a position in Regulus Therapeutics in Q4 2014 and held it in 8 quarters.
  • UBS AM's Regulus Therapeutics position peaked at $23.2M in Q4 2015.
  • 68 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2016.

Based on UBS AM's 13F filing for Q4 2016, filed 14 Feb 2017.